Home Beovu Lawsuits

Beovu Lawsuits

Beovu lawsuits claim the drug’s manufacturer failed to warn patients and doctors about potential vision side effects. People who took Beovu and suffered vision loss, retinal vasculitis, occlusive retinal vasculitis and other vision problems may qualify to file a lawsuit for compensation.

This is an active lawsuit
See if you can file

See If You Qualify for a Beovu Lawsuit

If you suffered vision loss or other serious vision problems after taking Beovu, you may be entitled to compensation. Get a free case review today.

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. After submitting, you will be contacted by one of Drugwatch's trusted legal partners. This is legal advertising.
Last Modified: February 23, 2021
Fact Checked
Fact-Checked

Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Beovu (brolucizumab-dbll) is a prescription medication approved by the U.S. Food and Drug Administration to treat wet age-related macular degeneration (AMD). It’s administered by injection into the eye.

From its approval in October 2019 to February 2020, doctors have administered about 46,000 Beovu injections, Novartis told Healio.

In February 2020, the American Society of Retina Specialists (ASRS) shared an update with its members about reports of 14 cases of vasculitis in patients who took Beovu, according to Novartis’ statement to Healio. Vasculitis is inflammation of the vascular branches of arteries in the retina.

Of those 14 cases, 11 people suffered occlusive retinal vasculitis. Occlusive retinal vasculitis is a condition that happens when blood vessels in the eye become blocked. The condition may lead to blindness.

After a month, cases increased to 25 cases of retinal vasculitis. Twenty-one of them involved occlusion.

There were no warnings about these specific adverse events on the drug’s prescribing information until June 2020. Lawyers say Novartis put people at risk of vasculitis, occlusive retinal vasculitis and blindness by not warning them.

Novartis stands by Beovu’s safety and efficacy. In a June 2020 statement, the company said these reports are “rare post-marketing safety events.”

Did you experience serious vision problems after taking Beovu?

Injuries in Lawsuits

Beovu’s prescribing insert lists several vision-related side effects of the drug. The most common are blurred vision, cataracts, eye hemorrhage and blood vessel inflammation in the back of the eye. The original prescribing label didn’t include warnings about retinal vasculitis and retinal occlusion.

After reviewing the information from American Society of Retina Specialists (ASRS), Novartis announced in April 2020 that it would evaluate reports of severe vision loss, retinal artery occlusion and/or vasculitis with Beovu.

The drug maker concluded that “there is a confirmed safety signal of rare adverse events of ‘retinal vasculitis and/or retinal vascular occlusion that may result in severe vision loss.’”

In February 2020, FDA approved Novartis’ label change to include “additional safety information regarding retinal vasculitis and retinal vascular occlusion.”

Beovu vision injuries in lawsuits include:
  • Blindness
  • Occlusive retinal vasculitis
  • Retinal artery occlusion
  • Retinal vasculitis
  • Vision loss

Woman Has Retinal Vasculitis After Beovu

In August 2020, Dr. Srinivas Sai A. Kondapalli of Everett and Hurite Ophthalmic Association in Pittsburgh, Pennsylvania, reported on a case of a 77-year old woman who suffered acute visual acuity loss in her right eye after taking two doses of Beovu. JAMA Ophthalmology published the case report.

Doctors diagnosed the woman with retinal vasculitis. She had previously taken bevacizumab and aflibercept for wet age-related macular degeneration and did not have any eye inflammation with either drug.

Symptoms of Retinal Vasculitis

Retinal vasculitis is a condition that causes inflammation in the retina, the part of the eye that senses light and allows you to see. Potential causes include infectious disease, a neurological disorder or autoimmune disease.

Retinal vasculitis can be aggressive and recurrent. In uncontrolled disease, it can lead to severe vision loss. It progresses through stages.

If retinal vasculitis occurs with occlusion from a blockage in a vein, it can cause sudden blurring or vision loss. Some vision loss starts as a slight blur then gets worse over hours or days.

Symptoms of retinal vasculitis include:
  • Altered color vision
  • Blurring of vision
  • Flashes
  • Floaters (spots or streaks in vision)
  • Metamorphopsia (a defect that causes linear objects, like lines, to look rounded or curvy)
  • Pain
  • Scotoma (partial loss of vision or a blind spot)

Will There Be a Recall?

So far, Novartis and the FDA haven’t mentioned a Beovu recall.

While the FDA approved Novartis’ label change, it did not issue a safety communication to the public or announce any regulatory actions.

Another drug involved in vision loss lawsuits is Elmiron. According to Elmiron lawsuits, the drug’s maker — Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. — failed to warn people that the medication could cause a rare disorder called retinal pigmentary maculopathy.

Like retinal vasculitis, retinal pigmentary maculopathy can cause permanent vision loss.

FDA hasn’t announced a recall for Elmiron or issued a safety announcement. Janssen added a warning for retinal pigmentary maculopathy in June 2020.

Learn About Elmiron Lawsuits

Please seek the advice of a medical professional before making health care decisions.
Related Pages